Value of duloxetine combined with olanzapine in the treatment of somatization disorders
度洛西汀联合奥氮平在躯体化障碍治疗中的应用价值分析

摘要

目的 分析对躯体化障碍患者使用度洛西汀联合奥氮平药物进行治疗的效果。方法 从2019年1月-2022年1月因躯体化障碍入院的患者内随机选择30例，根据两组患者接受的治疗形式进行分组，即实验组与对照组，各15例。对照组整体均接受度洛西汀药物治疗，实验组整体均接受度洛西汀联合奥氮平药物治疗，对比相关指标。结果 实验组SCL-90各项（躯体化、强迫、人际关系敏感、抑郁、焦虑、敌对、恐怖、偏执、精神病性）数值均低于对照组，P＜0.05。实验组WHOQOF-100各项（生理领域、心理领域、独立性领域、社会关系、环境领域、精神支柱/宗教/感染信仰等）数值均高于对照组，P＜0.05。结论 对躯体化障碍患者进行临床治疗的过程中，使用度洛西汀联合奥氮平进行治疗，可以改善患者的WHOQOF-100、SCL-90指标显著改善，值得推广。

Abstract

Objective: To analyze the efficacy of duloxetine combined with olanzapine in the treatment of somatization disorders.
Methods: from january2019 to january2022, 30 patients with somatization disorder were randomly selected and divided into two groups according to the treatment forms received by the two groups, namely, the experimental group and the control group, with 15 patients in each group. The control group received duloxetine and the experimental group received duloxetine combined with olanzapine. The related indexes were compared.
Results: the values of SCL-90 (somatization, compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobia, paranoia and psychosis) in the experimental group were lower than those in the control group (P < 0.05). The values of whoqof-100 in the experimental group were higher than those in the control group (P < 0.05).
Conclusion  : during the clinical treatment of patients with somatization disorder, duloxetine combined with olanzapine can significantly improve the whoqof-100 and SCL-90 indexes of patients, which is worth popularizing.